CRDF Q3 2018 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$133M

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$88,361-28.4% YoY

Gross Profit

$61,68469.8% margin

Operating Income

-$4M-4363.1% margin

Net Income

-$4M-4266.1% margin

EPS (Diluted)

$-1.10

QoQ Revenue Growth

-21.0%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$278,221

Balance Sheet

Total Assets

$18M

Total Liabilities

$4M

Stockholders' Equity

$14M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$88,361	$123,329	-28.4%
Gross Profit	$61,684	-$349,873	+117.6%
Operating Income	-$4M	-$6M	+33.5%
Net Income	-$4M	-$4M	+12.2%